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Iron is essential for normal brain function and is a 
cofactor for synthesis of neurotransmitters and 
many key brain tissues, including myelin [Ortiz 
et al. 2004]. An imbalance of iron metabolism can 
influence the pathogenesis of a number of neuro-
logical disorders [Hallgren and Sourander, 1958]. 
The mechanism by which this occurs is unclear, 
A pilot, longitudinal, 24-week study to 
evaluate the effect of interferon beta-1a 
subcutaneous on changes in susceptibility-
weighted imaging-filtered phase 
assessment of lesions and subcortical deep-
gray matter in relapsing–remitting multiple 
sclerosis
Robert Zivadinov, Michael Dwyer, Silva Markovic-Plese, Brooke Hayward, Niels Bergsland, 
Mari Heininen-Brown, Ellen Carl, Cheryl Kennedy, Fernando Dangond and Bianca 
Weinstock-Guttman
Abstract
Background: Studies have shown a relationship between increased iron content and clinical 
progression, cognitive impairment, and brain atrophy in patients with multiple sclerosis. 
Altered phase, as determined by susceptibility-weighted imaging (SWI), can potentially capture 
iron content changes.
Objective: The objective of this study was to investigate phase changes in white matter (WM) 
lesions and subcortical deep-gray matter (SDGM) of patients with relapsing–remitting (RR) 
MS treated with interferon beta-1a administered subcutaneously versus untreated healthy 
controls (HCs).
Methods: We conducted a 24-week, nonrandomized, open-label pilot study of 23 patients 
with RRMS receiving interferon beta-1a administered subcutaneously and 15 HCs. Patients 
were imaged on a 3T scanner at baseline, 12, and 24 weeks; changes in phase behavior 
in WM lesions and regional SDGM [mean phase of low-phase voxels (MP-LPV)], and in 
SDGM volumes, were measured. Between- and within-group changes were tested using 
nonparametric statistics adjusted for multiple comparisons.
Results: The number (p = 0.003) and volume (p < 0.001) of phase WM lesions both significantly 
decreased among RRMS patients over 24 weeks. At baseline, MP-LPV was lower (suggestive 
of greater iron content) in total SDGM among RRMS patients versus HCs (p = 0.002). Week 24 
MP-LPV changes from baseline were not significantly different between groups in total SDGM 
or any region except the putamen (−0.0025 radians in RRMS patients versus 0.0035 radians in 
HCs; p = 0.041).
Conclusions: Over 24 weeks, phase lesions were reduced significantly in the RRMS group. 
These preliminary results suggest that SWI-filtered phase may become a useful tool for 
monitoring RRMS disease activity.
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but may involve the generation of reactive oxygen 
species that cause neurotoxicity, as brain tissue is 
particularly sensitive to oxidative stress [Sullivan, 
2004; Zivadinov et al. 2012].
Brain iron accumulation is associated with ageing 
in healthy individuals, and has been implicated as 
a risk factor for neurodegeneration [Bartzokis 
et al. 2007; Hagemeier et al. 2012a]. An increase 
in brain iron level has been suggested to be associ-
ated with the development, progression, and clin-
ical impact of multiple sclerosis (MS) 
[Al-Radaideh et al. 2013; Ceccarelli et al. 2011; 
Hagemeier et  al. 2012c, 2013b, 2013c; Jomova 
and Valko, 2011; Khalil et al. 2011]. The associa-
tion between gray matter (GM) damage and 
increased MS disability is increasingly reported, 
with iron accumulation being observed in struc-
tures where volume loss has also occurred 
[Hagemeier et al. 2013b].
Several magnetic resonance imaging (MRI) tech-
niques enable in vivo imaging of paramagnetic sub-
stances, such as iron, in the brain. One such 
approach, susceptibility-weighted imaging (SWI), 
may be useful for investigating white matter (WM) 
lesions and phase changes in subcortical deep GM 
(SDGM) structures [Haacke et al. 2004, Hagemeier 
et al. 2012c; 2013b]. SWI takes advantage of mag-
netic field changes caused by constituents such as 
iron through their influence on the phase of proton 
spin [Haacke et  al. 2004]. Both post mortem 
[Bagnato et  al. 2011; Liem et  al. 2012; Yao et  al. 
2012] and in vivo [Liem et al. 2012; Yao et al. 2012] 
studies have confirmed associations between local 
SWI-filtered phase shift and underlying magnetic 
susceptibility, which may be affected by increased 
tissue iron content.
The objective of this study was to investigate 
changes of WM lesions and SDGM SWI-filtered 
phase behavior, and of SDGM volumes in patients 
with relapsing–remitting (RR) MS over 24 weeks 
of treatment with interferon beta-1a administered 
subcutaneously (Rebif®, EMD Serono Inc., a 
subsidiary of Merck KGaA, Darmstadt, Germany) 
with reference to healthy controls (HCs) not 
receiving treatment.
Methods
Study design and patients
This was a 24-week, nonrandomized, open-label, 
two-arm pilot study [ClinicalTrials.gov identifier: 
NCT01085318] in patients with RRMS receiving 
interferon beta-1a administered subcutaneously 
compared with a HC reference group that was 
conducted at a single center in the United States 
[Zivadinov et al. 2014].
Patients with RRMS and HCs were eligible for 
inclusion if they were aged 18–65 years; eligible 
patients had a diagnosis of RRMS according to 
the McDonald 2010 criteria [Polman et al. 2010] 
and disease duration <20 years, and were treat-
ment-naïve or using any of the US Food and 
Drug Administration (FDA)-approved disease-
modifying drugs (except natalizumab, mitox-
antrone, or interferon beta-1a administered 
subcutaneously).
Baseline assessments included physical and neu-
rological exams, MRI scans, and laboratory tests. 
Neuroimaging assessments were performed at 
baseline, week 12, and at the week 24/exit visit. 
Neurological examinations were conducted at 
screening and the week 24/exit visit. Neurological 
exams were not blinded. A safety evaluation tele-
phone call was scheduled in week 28 (4 weeks 
after study exit). Patients with RRMS received 
interferon beta-1a administered subcutaneously 
titrated over 4 weeks to a final dose of 44 µg for 
injection three times weekly for 24 weeks.
Patients and controls gave written informed con-
sent before participation, and the protocol was 
approved by the University at Buffalo Health 
Sciences Institutional Review Board. Screening 
occurred within 2 weeks prior to entering the 
study.
Study endpoints
Changes in SWI-filtered phase behavior in WM 
lesion number and volume and in regional 
SDGM, and changes in regional volumes in the 
SDGM, were measured at baseline and at 12 and 
24 weeks in patients with RRMS treated with 
interferon beta-1a administered subcutaneously 
and in untreated HCs. These assessments were 
secondary endpoints in the study. The primary 
endpoints were changes in voxel-wise magnetiza-
tion transfer ratio in normal appearing brain tis-
sue and lesions in RRMS patients taking interferon 
beta-1a administered subcutaneously compared 
with that in HCs, as reported previously 
[Zivadinov et al. 2014]. Safety endpoints included 
the number of study-emergent adverse events 
over 24 weeks.
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MRI assessments
All scans were carried out on a 3T General Electric 
Signa Excite HD 12.0 (General Electric, Milwaukee, 
WI, USA) right-handed system using a multichan-
nel head and neck coil. SWI was acquired using a 
3D flow-compensated gradient echo sequence with 
64 slices, 2-mm slice thickness, field of view (FOV) 
= 25.6 cm × 19.2 cm, in-plane resolution of 0.5 
mm × 1 mm (flip angle = 12° echo time [TE]/rep-
etition time [TR] = 22/40 ms; acquisition time = 8 
min 46 s, bandwidth = 13.89 kHz) [Zivadinov et al. 
2012, 2014]. Additional sequences included dual 
fast spin-echo proton density (PD) and T2 weighted 
image (WI), fluid-attenuated inversion recovery 
(FLAIR), spin-echo T1WI and a 3D high-resolu-
tion T1WI fast spoiled gradient echo sequence with 
a magnetization-prepared inversion recovery pulse, 
as reported previously [Zivadinov et  al. 2014]. 
Although perfect blinding between groups is impos-
sible when viewing images, raters were unaware a 
priori of subjects’ group assignment.
Phase assessment in WM lesions. An overview of 
the SWI processing, lesion analysis method, and 
reproducibility results used in the present study is 
discussed elsewhere [Hagemeier et  al. 2012b, 
2014]. Each subject’s images and WM lesion 
maps were coregistered with functional MRI of 
the brain’s linear image registration tool (FLIRT) 
using 6 degrees of freedom (rigid body) [Jenkin-
son and Smith, 2011]. Images were resampled 
using trilinear interpolation, and WM lesion maps 
were resampled with nearest-neighbor interpola-
tion using the registration matrix of their associ-
ated images. Identification of WM lesions was 
done using a semi-automated edge-detection 
contouring/thresholding technique [Zivadinov 
et al. 2001, 2012].
Classification of phase WM lesions was performed 
using a manual region-of-interest approach that 
was previously shown to be reproducible 
[Hagemeier et al. 2012b, 2014]. WM lesions were 
identified separately on T2/PD/FLAIR, T1WI, 
and SWI-filtered phase maps in a blinded manner 
without a priori knowledge of where the WM 
lesions were located with respect to the other 
modality. Only round/oval WM lesions ⩾3 mm in 
size were included in the study. In addition, a sub-
set of WM lesions was visible on both SWI-filtered 
phase and T2/PD/FLAIR, and a subset was visi-
ble on both SWI-filtered phase and T1WI; these 
were identified automatically a posteriori as over-
lapping when one or more voxels overlapped after 
unblinding was performed.
Low mean phase identification in the SDGM. Seg-
mentation of SDGM structures for volumetric and 
SWI analysis was done using FLIRT on the 3D 
T1WI [Patenaude et  al. 2011]. Additional struc-
tures not identifiable this way (red nucleus, pulvinar 
nucleus, and substantia nigra) were manually delin-
eated on the most representative SWI-filtered phase 
slice by a single operator using JIM5 (Xinapse Sys-
tems Ltd., Northamptonshire, UK), as reported 
previously [Zivadinov et al. 2012]. An overview of 
the analysis method and reproducibility results used 
in the present study is discussed elsewhere [Zivadi-
nov et al. 2012]. In this study, the mean phase of 
low-phase voxels (MP-LPV) of each structure was 
determined by thresholding the phase images to 
retain only those voxels with phase values lower than 
two standard deviations below the reference group 
means, as explained elsewhere [Zivadinov et  al. 
2012; Hagemeier et al. 2013a]. As a measure of the 
degree of phase abnormality, the mean phase values 
of the resulting thresholded voxels were calculated, 
yielding MP-LPV. Structure-specific maps of voxels 
with low phase are presented in radians, with lower 
MP-LPV values suggesting increased iron content.
Statistical methods
Sample size was based on clinical rather than sta-
tistical considerations. It was estimated that 
screening 55 subjects would achieve an intent-to-
treat population of 25 patients with RRMS and 
15 HCs [Zivadinov et al. 2014]. For testing differ-
ences in SWI endpoints between the patients with 
RRMS group and the HCs, the Wilcoxon rank-
sum test was used. For testing differences over 
time within the RRMS group, the Wilcoxon 
signed-rank test was used. All statistical tests were 
two-tailed and were considered significant at an α 
= 0.05 level of significance. Owing to the explora-
tory nature of this pilot study and the number of 
nonindependent endpoints, corrections for multi-
ple comparisons were made for post-baseline 
comparisons using the Holm–Bonferroni method. 
Unadjusted p values are reported with those 
remaining significant after adjustment noted.
Results
In total, 21 of the 23 enrolled patients with RRMS 
and all 15 HCs completed the study. There were 
two discontinuations: one due to investigator 
decision, and one lost to follow up [Zivadinov 
et al. 2014]. Baseline characteristics were compa-
rable between the study groups, and patients in 
the RRMS group were representative of a RRMS 
patient population (Table 1).
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Analysis of phase lesion number and volume
Both the number and volume of SWI-filtered 
phase WM lesions significantly decreased in the 
RRMS interferon beta-1a administered subcuta-
neously group from baseline to 24 weeks (Figure 
1 and Table 2). This was consistent for both the 
Table 1. Baseline characteristics and drug exposure/compliance of patients with RRMS and healthy controls.
Patients with RRMS HCs
 n = 23 n = 15
Age, years, mean (SD)a 39.9 (10.17) 36.7 (10.31)  
Female, n (%)a 14 (61) 8 (53)  
Race, n (%)a  
 White 20 (87) 14b (93)  
 Black 3 (13) 0  
 Other: Indian 0 1 (7)  
Mean (SD) weight, kga 79.9 (22.25) 87.0 (18.33)  
Mean (SD) height, cma 171.0 (8.48) 168.5 (6.99)  
Mean (SD) BMI, kg/m2a 27.2 (6.90) 30.5 (5.37)  
Mean (SD) years since MS diagnosis, 
range
6.6 (5.65), 0–20 —  
Mean (SD) years since most recent 
relapse, range
1.0 (1.14), 0.1–5.0 —  
Mean (SD) number of relapses in 
past 12 monthsc
1.26 (1.18) —  
 0, n (%) 7 (30)  
 1, n (%) 7 (30)  
 2, n (%) 7 (30)  
 4, n (%) 2 (9)  
Most recent disease-modifying drug 
use, n (%)
—  
 Intramuscular IFN beta 1-a 8 (35)  
 Subcutaneous IFN beta 1-a 5 (22)  
 Glatiramer acetate 4 (17)  
 Natalizumab 2 (9)  
 Intravenous immunoglobulin 1 (4)  
 None 3 (13)  
Median (range) Expanded Disability 
Status Scale score
2.5 (1–5.5) —  
Mean (SD) ambulation distance, 
meters
475 (94.2) —  
Study drug exposure and 
complianced
Interferon beta-1a administered subcutaneously three times  
per week
 n = 23
 8.8 µg 22 µg 44 µg
Total dose received, µg, mean (SD) 52.5 (7.60) 133.9 (9.17) 2,174.9 (584.47)
Doses missed, mean (SD) 0 (0.2) 0 (0) 5 (7.6)
Compliance, %, mean (SD) 99 (3.5) 100 (0) 92 (12.2)
aNo significant differences were seen between groups by the Student’s t-test (for age, weight, height, and body mass 
index) or Fisher’s exact test (for race and gender).
bIncludes one patient of Hispanic ethnicity (all other subjects were not Hispanic).
cPatients reported the same number of relapses for the past 24 months.
dCompliance was calculated at study visits using subject diaries and returned drug. Exposure was calculated from compliance.
BMI, body mass index; HC, healthy control; IFN, interferon; RRMS, relapsing–remitting multiple sclerosis; SD, standard 
deviation.
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SWI-filtered phase WM lesions alone (Figure 2) 
and for the overlapping SWI-filtered phase + T2/
PD/FLAIR, and to some extent was also true for 
overlapping SWI-filtered phase + T1WI (for 
number of lesions but not volume). The decreases 
from baseline for the SWI-filtered phase WM 
lesions alone remained significant after multiple 
comparison adjustment. Trends towards reduced 
SWI-filtered phase WM lesion number and vol-
ume were observed at the 12-week MRI.
Figure 1. Change from baseline to week 24 in volume (left panel) and number (right panel) of susceptibility-
weighted imaging (SWI)-filtered phase white matter (WM) lesions in patients with relapsing–remitting multiple 
sclerosis (RRMS).
In the box plots, the yellow + represents the mean; the solid line represents the median; the dashed line represents no change; 
the colored boxes represent the middle 50% of data; the top and bottom of the box represent the first and third quartiles; the 
open circles are outliers. The ‘whisker lines’ above and below the boxes represent the largest and smallest values that are not 
considered to be outliers. p values shown are for the difference between RRMS and healthy controls (HCs) from the Wilcoxon 
rank-sum test. FLAIR, fluid-attenuated inversion recovery; NS, not significant; PD, proton density; T1WI, T1 weighted image.
Table 2. Volume and number of SWI-filtered phase WM lesions at baseline and change from baseline to week 12 and week 24.




HCs p valuea Patients 
with 
RRMS




Volume on SWI-filtered 














n (missing) 22 (1) 14 (1) 22 (1) 14 (1) 21 (2) 12 (3)  
Number of lesions on 










NS −4 (8.1)b −1 (1.4) NS
n (missing) 22 (1) 15 (0) 22 (1) 15 (0) 21 (2) 13 (2)  
Volume on SWI + PD/T2/
FLAIR in mm3, mean (SD)
1,342 
(1,555.9)





n (missing) 22 (1) 0 (15) 22 (1) 0 (15) 20 (3) 0 (15)  
Number of lesions on 















n (missing) 22 (1) 15 (0) 22 (1) 15 (0) 21 (2) 13 (2)  









n (missing) 20 (3) 0 (15) 20 (3) 0 (15) 20 (3) 0 (15)  
Number of lesions on 














n (missing) 22 (1) 15 (0) 22 (1) 15 (0) 21 (2) 13 (2)  
aFor the difference between patients and HCs from the Wilcoxon rank-sum test.
bSignificant difference from zero within group from the Wilcoxon signed-rank test.
cNot significant after adjustment for multiple comparisons with the Holm–Bonferroni correction. Comparisons at baseline were not adjusted for 
multiple comparisons.
FLAIR, fluid-attenuated inversion recovery; HC, healthy control; NS, not significant; PD, proton density; RRMS, relapsing–remitting multiple scle-
rosis; SD, standard deviation; SWI, susceptibility-weighted imaging; T1WI, T1 weighted image; WM, white matter.
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Analysis of MP-LPV changes in the SDGM over 
the 24-week follow up
MP-LPV was significantly lower at baseline, sug-
gestive of increased iron content in patients with 
RRMS compared with HCs in the total SDGM 
(p = 0.002), as well as in the caudate (p < 0.001), 
putamen (p = 0.007), globus pallidus (p = 0.023), 
thalamus (p = 0.017), and pulvinar nucleus 
(p = 0.013) regions (Table 3).
Change from baseline to week 24 in MP-LPV was 
not significantly different between groups in the 
total SDGM or in any of the regions, except for the 
putamen (−0.0025 radians versus 0.0035 radians in 
RRMS patients and HCs, respectively;  p = 0.041); 
however, this difference was not significant after 
adjustment for multiple comparisons (Table 3 and 
Supplement Figure). Within the RRMS group only, 
the caudate showed a significant difference in 
MP-LPV during the first 12 weeks of the study (an 
increase in radians, suggestive of a decrease in iron 
content) compared with the second 12 weeks (a 
decrease in radians, suggestive of an increase in iron 
content, p = 0.001), which was still significant after 
adjustment for multiple comparisons (p = 0.0121; 
data not shown).
Analysis of normalized SDGM volume changes 
over the 24-week follow up
Patients with RRMS had significantly lower vol-
umes compared with HCs for the total SDGM, 
putamen, globus pallidus, and thalamus (p < 0.01) 
at baseline, but no significant differences were meas-
ured for the caudate or hippocampus (Table 4).
As a group, patients with RRMS had significant 
decreases in volume from baseline to 24 weeks in 
some of the brain regions (Table 4). Only the dif-
ferences in the total SDGM and thalamus 
Figure 2. Phase-visible lesion resolution over time. Images were linearly coregistered to Montreal Neurologic 
Institute (MNI) space to allow unbiased visualization. The top row shows the full slices for reference, while 
the lower row provides enlargements of the boxes centered around the lesion. From left to right, images are 
of baseline, 3-month follow up, and 6-month follow up. The lesion in the center is clearly visible at baseline, 
partially resolved at 3 months, and almost completely resolved at 6 months.
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Table 3. MP-LPV values at baseline and absolute change from baseline at week 24.
Baseline Week 24 change from baseline
 Patients with RRMS HCs Patients with 
RRMS
HCs  









n (missing) 23 (0) 15 (0) 21 (2) 13 (2)  
Total SDGM −0.170 (0.030) −0.140 (0.019) 0.002 0.0009 (0.0217) 0.0051 
(0.0070)b,c
NS
Caudate −0.190 (0.025) −0.169 (0.019) <0.001 0.0017 (0.0123) 0.0040 (0.0112) NS
Putamen −0.205 (0.050) −0.169 (0.023) 0.007 −0.0025 (0.0448) 0.0035 (0.0098) 0.041c
Globus pallidus −0.207 (0.054) −0.175 (0.019) 0.023 0.0020 (0.0277) 0.0045 (0.0123) NS
Thalamus −0.106 (0.020) −0.091 (0.013) 0.017 0.0003 (0.0137) −0.0004 (0.0079) NS
Pulvinar nucleus −0.178 (0.044) −0.145 (0.022) 0.013 −0.0082 (0.0276) −0.0099 (0.0285) NS
Hippocampus −0.176 (0.052) −0.154 (0.037) NS 0.0081 (0.0266) 0.0107 
(0.0193)b,c
NS
Red nucleus −0.246 (0.037) −0.242 (0.032) NS −0.0027 (0.0306) 0.0077 (0.0300) NS
Substantia nigra −0.359 (0.069) −0.495 (0.705) NS 0.0061 (0.0420) 0.0228 (0.0330) NS
aFor the difference between patients and HCs from the Wilcoxon rank-sum test.
bSignificant difference from zero within group from the Wilcoxon signed-rank test.
cNot significant after adjustment for multiple comparisons with the Holm–Bonferroni correction. Comparisons at baseline were not adjusted for 
multiple comparisons.
Lower MP-LPV values are believed to be indicative of higher iron content.
HC, healthy control; MP-LPV, mean phase of low-phase voxels; NS, not significant; RRMS, relapsing–remitting multiple sclerosis; SD, standard 
deviation; SDGM, subcortical deep-gray matter.
remained significant after adjustment for multiple 
comparisons. There were no significant changes 
from baseline to 24 weeks within the HC group.
From baseline to 24 weeks, changes in normal-
ized volume were significantly different between 
patients with RRMS and HCs in the total SDGM 
(–2.09% and 0.20% in RRMS and HC groups, 
respectively; p = 0.011) and hippocampus 
(–1.71% and 2.07% in RRMS and HC groups, 
respectively; p = 0.041). The differences between 
groups did not remain significant after adjust-
ment for multiple comparisons (Figure 3 and 
Table 4).
Table 4. Regional normalized SDGM volumes at baseline and percentage change from baseline at week 24.
Baseline volume (mm3) % change from baseline at week 24  
 Patients with RRMS HCs Patients with RRMS HCs
 Mean (SD) Mean (SD) p valuea Mean (SD) p valueb Mean (SD) p valuea
n (missing) 23 (0) 15 (0) 21 (2) 13 (2)  
SDGM 42,620 (4,475) 46,934 (2,748) 0.002 −2.09 (2.81) <0.001 0.20 (1.82) 0.011c
Caudate 6,526 (987) 7,002 (622) NS −1.53 (5.09) 0.039c −2.12 (5.28) NS
Putamen 9,076 (1,111) 10,091 (750) 0.004 −4.55 (10.93) 0.012c 0.58 (3.298) NS
Globus pallidus 3,250 (386) 3,575 (182) 0.009 −0.79 (5.72) NS −0.54 (4.36) NS
Thalamus 13,908 (1,743) 15,551 (1,294) 0.004 −1.44 (1.76) <0.001 0.06 (1.96) NS
Hippocampus 6,931 (658) 7,315 (563) NS −1.71 (4.78) NS 2.07 (5.04) 0.041c
aFor the difference between patients with RRMS and HCs from the Wilcoxon rank-sum test.
bFor the difference from zero within patient group from the Wilcoxon signed-rank test.
cNot significant after adjustment for multiple comparisons with the Holm–Bonferroni correction. Comparisons at baseline were not adjusted for 
multiple comparisons.
HC, healthy control; NS, not significant; RRMS, relapsing–remitting multiple sclerosis; SD, standard deviation; SDGM, subcortical deep-gray matter.
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Safety and tolerability
Almost all patients with RRMS (22/23) and 8/15 
HCs had ⩾1 study-emergent adverse effect; 16 of 
the patients had adverse effects considered to be 
related to study treatment (Supplement Table).
Discussion
In this pilot longitudinal study, one of the first to 
investigate the SWI-filtered phase changes in WM 
lesions in RRMS patients over 24 weeks, both the 
number and volume of SWI-filtered phase WM 
lesions were significantly decreased from baseline 
in RRMS patients receiving treatment with inter-
feron beta-1a administered subcutaneously. This 
effect has to be interpreted with caution, but 
could potentially be related to the effect of inter-
feron beta-1a administered subcutaneously on 
the iron and myelin content in the WM lesions 
[Yao et al. 2012; Hagemeier et al. 2014; Bian et al. 
2013; Eissa et al. 2009; Haacke et al. 2009; Mehta 
et  al. 2013; Yablonskiy et  al. 2012]. However, 
without the use of randomized, controlled study 
design, it is difficult to attribute the observed 
effect directly to the treatment with interferon 
beta-1a. The accumulation of iron in some, but 
not all, WM lesions suggests a specific, potentially 
disease-relevant process; however, its pathophysi-
ological significance remains unknown [Bian 
et al. 2013; Mehta et al. 2013]. It is also unknown 
whether the increased iron deposition in WM 
lesions of patients with MS is a result of debris 
from myelin/oligodendrocyte breakdown, con-
centrated iron in macrophages (that phagocytize 
the myelin/oligodendrocytes), or the product of 
hemorrhages from damaged brain vessels [Haacke 
et al. 2004, 2009], or whether it represents a direct 
contribution to brain pathology. A recent cross-
validation study of phase imaging with immuno-
histochemical examination of autoptic MS tissue 
[Mehta et al. 2013] reported that iron is present 
in nonphagocytosing, M1-polarized microglia/
macrophages at the rim of chronic active WM 
demyelinating lesions. This suggests that phase 
imaging has potential to visualize specific, chronic 
proinflammatory activity in established MS 
lesions. In fact, phase hypointense lesions are 
more prevalent in patients with active relapsing 
than with secondary progressive MS [Hagemeier 
et  al. 2012b; Mehta et  al. 2013]. The RRMS 
patients enrolled in this 24-week study had active 
disease, with 16 of 23 patients presenting with a 
Figure 3. Percentage change from baseline to week 24 in normalized volume of brain subcortical deep gray 
matter (SDGM) structural regions.
In the box plots, the yellow + represents the mean; the solid line represents the median; the dashed line represents no 
change; the colored boxes represent the middle 50% of data; the top and bottom of the box represent the first and third 
quartiles; the open circles are outliers. The ‘whisker lines’ above and below the boxes represent the largest and smallest 
values that are not considered to be outliers. p values shown are for the difference between relapsing–remitting multiple 
sclerosis (RRMS) and healthy controls (HCs) from Wilcoxon rank-sum test. NS, not significant.
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relapse in the 12 months prior to baseline. 
Therefore, a significant decrease in number and 
volume of existing SWI-filtered phase WM lesions 
over 24 weeks may represent the decrease of 
chronic pro-inflammatory activity in established 
MS lesions. However, little is known at this time 
about phase lesion changes over the short- or 
long-term follow up in MS patients, so the find-
ings from this study have to be interpreted with 
caution [Bian et al. 2013].
Although phase lesions may be indicative of iron, 
they may be even more affected by myelin changes 
[Yao et  al. 2012; Bian et  al. 2013; Chen et  al. 
2014]. In a recent study in patients with clinically 
isolated syndrome who converted to clinically 
definite MS within a 3-year follow-up period ver-
sus those who did not, converters had significantly 
(p = 0.008) more phase lesions, but not T2WM or 
T1WM lesions; although the phase contrast could 
have been influenced by demyelination or other 
factors, the predictive value of phase lesions could 
imply a role in early disease pathology [Hagemeier 
et al. 2014]. These findings are in line with obser-
vations that phase contrast observed in MS WM 
lesions is dynamic and may be visible at early dis-
ease onset [Yablonskiy et  al. 2012; Chen et  al. 
2014]. However, others have reported that ring-
like phase WM lesions remained unchanged over 
several years [Bian et al. 2013]. A better under-
standing of phase behavior in active and chronic 
WM lesions in MS patients necessitates further 
longitudinal studies with larger sample size and 
heterogeneous disease subgroups. However, the 
findings from the present study can help guide the 
design of these future investigations, given that 
trends towards lower SWI-filtered phase number 
and volume of WM lesions were observed as early 
as 2 months after interferon beta-1a administered 
subcutaneously was titrated to the full dose.
There were significantly decreased MP-LPV and 
normalized volumes of the various SDGM struc-
tures in patients with RRMS compared with HCs 
at baseline, further validating the biological rele-
vance of these MRI outcomes. However, the 
majority of these MRI outcomes did not appear 
to progress in patients with RRMS over 24 weeks.
SWI-filtered phase has been proposed as a 
method to indirectly measure increased iron con-
tent [Haacke et al. 2004; Hagemeier et al. 2013a]. 
MP-LPV was significantly lower in the RRMS 
group than in HCs at baseline in the total SDGM 
and a number of its component regions (caudate, 
putamen, globus pallidus, thalamus, and pulvinar 
nucleus), suggesting higher iron content in the 
SDGM of MS patients. After 24 weeks, patients 
with RRMS showed no significant changes in 
MP-LPV compared with HCs, other than a pos-
sible effect in the putamen that was not supported 
after adjustment for multiple comparisons.
Paramagnetic substances, mostly in the form of 
ferritin and iron, influence the phase of proton 
spin. The changes in mean phase measures are 
most likely caused by iron; however, it is possible 
that phase shifts could also potentially be caused 
by other factors [Bagnato et  al. 2011; Yao et  al. 
2012], for example, by the diamagnetic properties 
of myelin [Schweser et  al. 2011]. Among this 
study’s investigations were phase changes in the 
SDGM structures, an approach believed to mini-
mize the confounding effects of myelin 
[Langkammer et al. 2012a]. However, it has to be 
noted that some SDGM structures, most notably 
the thalamus and hippocampus, have relatively 
high myelin content, which could potentially have 
influenced phase measurements.
Baseline volumes of SDGM regional structures 
were lower in patients with RRMS than in HCs, 
possibly indicating regional brain atrophy. A 
recent study with 5 years’ follow up provided evi-
dence that SDGM atrophy is greater in patients 
with disability progression than in stable patients 
[Zivadinov et  al. 2013]. The specific volume 
reductions in SDGM regions (putamen, global 
pallidus, and thalamus) are in line with previous 
reports, in which greater atrophy of certain 
SDGM regions in RRMS patients has been 
described [Zivadinov et al. 2013].
There are a number of limitations to this study. 
Given that no differences in MP-LPV changes 
were seen between RRMS patients and HCs over 
24 weeks, one could question whether the 
24-week follow up is sufficiently long enough to 
measure detectable SWI-filtered phase changes 
in the SDGM, and whether longer follow-up 
studies are needed to elucidate this issue further. 
While the treatment with interferon beta-1a 
administered subcutaneously may have also 
influenced SWI-filtered phase changes in the 
SDGM of the RRMS patients compared with 
HCs, it is not possible to establish a ‘cause–effect’ 
relationship without a control group of MS 
patients. Therefore, potential benefit of inter-
feron beta-1a administered subcutaneously on 
changes in the iron content of the SDGM as 
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measured by SWI-filtered phase should be estab-
lished in a head-to-head comparison with 
untreated or comparator-treated patients. 
However, the inclusion of a healthy group in a 
current study provided a valuable baseline, allow-
ing evaluation of this technique for normal varia-
tion between individuals against which changes 
in SWI-filtered phase could be compared. It 
should be noted that an ultimate goal of MS ther-
apy would be to normalize patient SWI-filtered 
phase changes over time towards the age-related 
changes observed in HCs. There are inherent 
limitations of the SWI-filtered phase-based imag-
ing method. Although this method is sensitive to 
iron changes, it can be affected by a number of 
other factors, in particular myelin, calcium phos-
phates, and deoxygenated blood [Langkammer 
et al. 2012b]. In addition, different forms of iron 
and containment structures (hemosiderin, ferri-
tin) cannot be distinguished although they have 
different biological impacts [Haacke et al. 2009]. 
The phase changes, reflecting the tissue magnetic 
properties, may also be explained by changes of 
the chemical form of iron, rather than the total 
iron concentration [Schweser et al. 2011]. SWI-
filtered phase depends not only on the tissue 
magnetic susceptibility, and thus indirectly on 
the tissue iron concentration, but also on the tis-
sue structure, which can be influenced by amount 
of atrophy [Schweser et al. 2013]. Therefore, in 
future studies, more advanced techniques such as 
quantitative susceptibility mapping and MR 
relaxometry may help to provide more exact iron 
concentration changes over time [Schweser et al. 
2011]. The results of phase estimation of red 
nucleus, substantia nigra, and pulvinar have to be 
interpreted with caution, as the iron concentra-
tion of these regions was performed on the most 
representative slice, rather than over the whole 
volume of the structure. Also, our segmentation 
method did not correct for presence of large veins 
in the SDGM [Zivadinov et al. 2012]. It is there-
fore possible that larger veins and/or differences 
in oxygen extraction might have some impact on 
our results. However, we did not find previously 
that segmentation and exclusion of the veins 
affected the reproducibility of our method or the 
overall iron concentration between MS patients 
and controls in the SDGM (unpublished data). 
Furthermore, manual or automated removal of 
the veins from SDGM may also underestimate 
true differences between controls and MS 
patients, since iron commonly deposits around 
perivascular spaces in MS patients [LeVine, 
1997].
In conclusion, RRMS patients showed significant 
decreases in both number and volume of SWI-
filtered phase WM lesions over the 24-week follow 
up. No significant differences between patients 
with RRMS and HCs in change from baseline in 
MP-LPV or normalized volumes were detected 
after 24 weeks after adjusting for multiple com-
parisons. While these preliminary results should 
be interpreted with caution, the study showed that 
SWI-filtered phase may become a useful tool for 
monitoring disease activity among RRMS patients.
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